G. Catimel

2.4k total citations
45 papers, 1.7k citations indexed

About

G. Catimel is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, G. Catimel has authored 45 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 16 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in G. Catimel's work include Cancer Treatment and Pharmacology (15 papers), Cancer therapeutics and mechanisms (14 papers) and Lung Cancer Research Studies (11 papers). G. Catimel is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Cancer therapeutics and mechanisms (14 papers) and Lung Cancer Research Studies (11 papers). G. Catimel collaborates with scholars based in France, Netherlands and Belgium. G. Catimel's co-authors include M. Clavel, Jaap Verweij, M. Spielmann, Jacques Bonneterre, M. Namer, Benjamin Winograd, M. Bontenbal, Pierfranco Conté, J.-M. Nabholtz and Karen A. Gelmon and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

G. Catimel

45 papers receiving 1.7k citations

Peers

G. Catimel

ONCOL

PRM

SURGE

M C Etienne France

Marie-Christine Étienne-Grimaldi France

Antti Jekunen Finland

P. Hupperets Netherlands

K. Syrigos Greece

S E Sartorius United States

Joseph D. McCracken United States

Lara Maria Pasetto Italy

David Nathanson United States

Dolores Gallardo‐Rincón Mexico

M C Etienne France

G. Catimel

2.1k ×1.6

ONCOL

859 ×1.6

598 ×1.5

PRM

266 ×0.8

276 ×1.2

SURGE

Citations per year, relative to G. Catimel G. Catimel (= 1×) peers M C Etienne

Countries citing papers authored by G. Catimel

Since Specialization

Citations

This map shows the geographic impact of G. Catimel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Catimel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Catimel more than expected).

Fields of papers citing papers by G. Catimel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Catimel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Catimel. The network helps show where G. Catimel may publish in the future.

Co-authorship network of co-authors of G. Catimel

This figure shows the co-authorship network connecting the top 25 collaborators of G. Catimel. A scholar is included among the top collaborators of G. Catimel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Catimel. G. Catimel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bonneterre, Jacques, M. Tubiana-Hulin, & G. Catimel. (2004). Paclitaxel, Epirubicin and Cyclophosphamide Combination in First-Line Treatment of Metastatic Breast Cancer: A Dose Escalation Study. Oncology. 66(3). 185–191. 6 indexed citations

Bachelot, Thomas, Isabelle Ray‐Coquard, G. Catimel, et al.. (2000). Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Annals of Oncology. 11(2). 151–156. 98 indexed citations

Planting, A.S.T., G. Catimel, P.H.M. de Mulder, et al.. (1999). Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Annals of Oncology. 10(6). 693–700. 82 indexed citations

Tranchand, Brigitte, G. Catimel, Catherine Lucas, et al.. (1998). Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 41(4). 281–291. 23 indexed citations

Giaccone, Giuseppe, Sabine C. Linn, Jan Welink, et al.. (1997). A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.. Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam). 3(11). 2005–15. 71 indexed citations

Chevallier, B, P Cappelaere, Ted A.W. Splinter, et al.. (1997). A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Supportive Care in Cancer. 5(1). 22–30. 20 indexed citations

Freyer, Gilles, G. Catimel, & Yacine Merrouche. (1996). Utilité des progestatifs de synthèse dans le traitement de la cachexie néoplasique. La Revue de Médecine Interne. 17(1). 79–84. 2 indexed citations

Armand, Jean‐Pierre, et al.. (1996). Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Annals of Oncology. 7(8). 837–842. 29 indexed citations

Catimel, G., Steinar Aamdal, W ten Bokkel Huinink, et al.. (1996). Phase II clinical trials with rhizoxin in breast cancer and melanoma. British Journal of Cancer. 73(3). 397–399. 27 indexed citations

10.

Verweij, Jaap, J. Wanders, Thierry Gil, et al.. (1996). Phase II study of rhizoxin in squamous cell head and neck cancer. British Journal of Cancer. 73(3). 400–402. 13 indexed citations

11.

Catimel, G.. (1996). Head and Neck Cancer. Drugs. 51(1). 73–88. 21 indexed citations

12.

Catimel, G., et al.. (1995). Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors. Cancer Chemotherapy and Pharmacology. 35(3). 246–248. 15 indexed citations

13.

Verweij, Jaco J., G. Catimel, Aarón Sulkes, et al.. (1995). Phase II studies of docetaxel in the treatment of various solid tumours. European Journal of Cancer. 31. S21–S24. 23 indexed citations

14.

Dirix, Luc, G. Catimel, René Verdonk, et al.. (1995). Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion. Investigational New Drugs. 13(2). 133–136. 2 indexed citations

15.

Catimel, G., G G Chabot, Jean‐Paul Guastalla, et al.. (1995). Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Annals of Oncology. 6(2). 133–140. 94 indexed citations

16.

Chabot, G G, D Abigerges, G. Catimel, et al.. (1995). Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Annals of Oncology. 6(2). 141–151. 149 indexed citations

17.

Catimel, G., Jan B. Vermorken, M. Clavel, et al.. (1994). A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Annals of Oncology. 5(6). 543–547. 108 indexed citations

18.

Merrouche, Yacine, G. Catimel, Paul Rebattu, et al.. (1994). A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy. Annals of Oncology. 5(6). 549–551. 9 indexed citations

19.

Verweij, Jaap, G. Catimel, M. Clavel, et al.. (1994). Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult. Annals of Oncology. 5(6). 539–542. 116 indexed citations

20.

Clavel, M. & G. Catimel. (1993). Breast cancer: Chemotherapy in the treatment of advanced disease. European Journal of Cancer. 29(4). 598–604. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact